-
June 8, 2026Umecrine Cognition resolves directed share issue of SEK 64 million to complete its clinical Phase 1b/2a studySTOCKHOLM – June 8 2026. Umecrine Cognition today announced that the company has resolved a directed share issue amounting to SEK 64 million,...
-
May 27, 2026Umecrine Cognition presents PBC patient survey data at EASL 2026 revealing central fatigue as the most burdensome symptomSTOCKHOLM – May 27, 2026. Umecrine Cognition today announced new patient survey data confirming that central fatigue, characterized by a loss of...
-
May 13, 2026Umecrine Cognition will present patient survey data at EASL 2026 suggesting golexanolone addresses critical unmet need in PBCSTOCKHOLM – May 13, 2026. Umecrine Cognition today announced new data from the UK-PBC national cohort, to be presented at the EASL Congress 2026 in...
Latest Annual Report
Subscribe
Our drug projects
GABAA receptor modulating steroid antagonists: our scientific focus
Our lead product candidate, golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone.